Renibus Therapeutics has three drugs in its pipeline, including one undergoing clinical trials in cardiac surgeries.Renibus Therapeutics, a Southlake-based clinical-stage biotech company developing medicines for chronic kidney disease and injuries, has closed a $35 million investment round and named a new chief executive.
Taking the reins from co-founder and former CEO Al Guillem is industry veteran Frank Stonebanks, who has spent 25 years in health care and venture capital roles. “Renibus has arrived at a critical inflection point in its commitment to transform the prevention and treatment of kidney diseases, and I see enormous potential in each of the programs,” Stonebanks said. “The closing of our $35 million capital raise will accelerate our momentum across the clinical portfolio.”The company’s funding round includes a $15 million extension led by family offices specializing in biotech investments.
Guillem’s 40 years of experience cover some of North Texas’ biggest pharmaceutical wins. He was part of a team at Adams Respiratory Therapeutics that created Mucinex. Adams was sold to Reckitt Benckiser
Most people wants to invest but find it difficult to invest in the right platform, Ever since I started investing with JulieCrypto_ I have been making huge profits weekly from home, I recommend you to meet her now and also be a beneficiary of good work.